Table 3 Patient characteristics.

From: Normalized periprostatic fat MRI measurements can predict prostate cancer aggressiveness in men undergoing radical prostatectomy for clinically localised disease

 

Group 1 6

Group 2

Group 3

p value

Post-operative Gleason score ≤

Post-operative Gleason score 7 (3 + 4)

Post-operative Gleason score 7 (4 + 3) and over

Mean ± Standard Deviation

 No.

n = 25

n = 71

n = 66

 

 Age (years)

65.72 ± 6.07

66.45 ± 5.82

68.70 ± 5.07

0.022a

 NPFV (cm3)

1.84 ± 0.76

2.45 ± 1.13

2.8 ± 1.56

0.001a

 AFA (cm2)

137.51 ± 65.12

126.12 ± 50.75

144.42 ± 61.27

0.177a

 SFT (cm)

3.84 ± 1.56

3.7 ± 1.18

3.8 ± 1.34

0.853a

 BMI (kg/m2)

27.87 ± 4.69

27.31 ± 3.61

27.73 ± 4.28

0.781a

 Initial PSA (ng/ml)

9.86 ± 5.29

11.06 ± 5.71

15.21 ± 11.11

0.006b

 PV (cm3)

63.29 ± 26.99

54.71 ± 32.07

51.01 ± 19.94

0.051b

WHO classification N (%)*

 No.

n = 23

n = 69

n = 64

0.946c

 Normal weight

7 (30.4)

22 (31.9)

18 (28.1)

 Overweight

9 (39.1)

31 (44.9)

30 (46.9)

 Obesity

7 (30.4)

16 (23.2)

16 (25)

Pathological stage N (%)*

 No.

n = 25

n = 71

n = 66

0.001c

 T2

20 (80)

43 (60.6)

25 (37.9)

 T3

5 (20)

28 (39.4)

41 (62.1)

D’Amico risk classification N (%)*

 No.

n = 25

n = 71

n = 66

<0.001c

 Low

18 (72)

18 (25.4)

2 (3)

 Intermediate

6 (24)

40 (56.3)

27 (40.9)

 High

1 (4)

13 (18.3)

37 (56.1)

  1. NPFV = Normalised periprostatic fat volume; AFA = Abdominal fat area; SFT = Subcutaneous fat thickness; BMI = Body mass index; PSA = Prostate specific antigen; PV = Prostate volume.
  2. Patients were stratified according to post-operative Gleason score.
  3. aANOVA, bKruskal-Wallis test, c χ 2 test.
  4. *(%) within each group.
  5. P value is significant <0.05.
Back to article page